AIM2 and malignant mesothelioma: On the other hand, tumor treating fields (TTFields), an approved therapy for GBM and malignant mesothelioma, induces cGAS/STING signaling and absent in melanoma-2 (AIM-2)-dependent type 1 IFN and proinflammatory cytokine-based antitumor immunity in syngeneic mouse GBM model developed using KR158 and GL261 glioma cells (Table 1) [192].